News

The partial hold was placed on the study in August of this year, requesting chemistry, manufacturing, and controls data and clarifications to several trial design questions. Now that

The companies formed a clinical trial collaboration to evaluate the combination treatment. The dose-escalation part assessing IPI-549 as a monotherapy in Infinity’s phase 1 trial is continuing, and

Data from the company's Phase 3 sickle cell disease trial demonstrated a reduction in the frequency of sickle cell crises and hospitalizations, as well as a reduction in

The agreement was facilitated by the Johnson & Johnson Innovation Centre in London. BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates

ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-positive mature T-cell

Mylan has submitted a biologics license application (BLA) for MYL-1401O via the 351(K) pathway. The proposed biosimilar version of trastuzumab is indicated to treat several breast and gastric

The company submitted a supplemental new drug application (sNDA) to teh FDA for Stivarga tablets for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC). The drug

Both companies’ products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to

Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive arrangement.  LX9211 is currently completing IND-enabling studies, with Phase 1 clinical